Ultragenyx Sells Priority Review Voucher for $210M in Non-Dilutive Cash
RARE is trading near its 52-week low of $12.73 (14% above the low).
Summary
Ultragenyx agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210 million in cash upon closing, providing significant non-dilutive capital. Under the deal, the company will pay 20% of the gross proceeds to the NIH after closing. The voucher was awarded by the FDA on August 19, 2026, following the approval of GENGLYCOS (pariglasgene brecaparvovec-opnr) for patients eight years and older. The asset purchase agreement was entered into on October 6, 2026. The deal is subject to HSR clearance and customary closing conditions. This follows a string of regulatory wins and a Phase 3 failure in September; the cash bolsters the balance sheet and supports the path to profitability. No closing date was specified.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The PRV sale agreement was entered into on October 6, 2026, and the $210 million is payable in cash upon closing.
- Agreement Date — The asset purchase agreement was entered into on October 6, 2026.
- Payment Terms — The buyer will pay the $210 million in cash upon the closing of the transaction.
- NIH Payment — 20% of gross proceeds will be payable to the NIH after the closing of the transaction.
- PRV Award — The PRV was awarded by the FDA on August 19, 2026.
- Approval Details — GENGLYCOS (pariglasgene brecaparvovec-opnr) was approved for patients eight years and older.
- NIH License — The NIH patent license agreement is dated December 10, 2018.
All 6 details
- The asset purchase agreement was entered into on October 6, 2026.
- The PRV was awarded by the FDA on August 19, 2026.
- GENGLYCOS (pariglasgene brecaparvovec-opnr) was approved for patients eight years and older.
- The buyer will pay the $210 million in cash upon the closing of the transaction.
- The NIH patent license agreement is dated December 10, 2018.
- 20% of gross proceeds will be payable to the NIH after the closing of the transaction.
At the time of this announcement, RARE was trading at $14.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $12.73 to $39.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.